Last reviewed · How we verify

Conventional 24-week glucocorticoid regimen

First Affiliated Hospital of Wenzhou Medical University · FDA-approved active Small molecule

Glucocorticoids suppress immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.

Glucocorticoids suppress immune and inflammatory responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Inflammatory and autoimmune conditions requiring sustained immunosuppression (specific indication not detailed in source).

At a glance

Generic nameConventional 24-week glucocorticoid regimen
SponsorFirst Affiliated Hospital of Wenzhou Medical University
Drug classGlucocorticoid
TargetGlucocorticoid receptor (GR)
ModalitySmall molecule
Therapeutic areaImmunology / Rheumatology / Inflammatory diseases
PhaseFDA-approved

Mechanism of action

Conventional glucocorticoid regimens work by activating intracellular glucocorticoid receptors, which translocate to the nucleus and modulate gene expression to reduce inflammation and immune cell activation. Over a 24-week treatment course, this leads to suppression of inflammatory mediators, reduced immune cell proliferation, and decreased vascular permeability. The regimen is typically used in conditions requiring sustained anti-inflammatory or immunosuppressive effects.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: